June 10, 2025 – Lubrizol announces that an Apisolex™ polymer excipient-enabled drugformulation is in Phase 1 clinical trials. Introduced to the market in 2022, Apisolex polymer excipient is a polyamino acid-basedpolymer that enhances the solubility of BCS Class II and IV active pharmaceuticalingredients (API). Apisolex polymer excipient is manufactured following GoodManufacturing Practices (GMP) guidelines and […]
The post Lubrizol announces an important milestone for its novelpatented excipient, Apisolex™ polymer appeared first on Pharmafile.
